Premier Biotech Expands Product Portfolio with NexScreen and TransMed Acquisitions
Premier Biotech has announced the acquisitions of NexScreen and TransMed, which will expand its global footprint and product offerings in the drug and alcohol testing solutions sector. The acquisitions aim to enhance customer relationships across various markets, including healthcare, government, and workplace sectors.
CLEVELAND & DALLAS–(BUSINESS WIRE)–Align Capital Partners’ (“ACP”) drug and alcohol testing solutions provider, Premier Biotech (“Premier” or the “Company”), announced the acquisitions of NexScreen and TransMed. These strategic acquisitions expand Premier’s global footprint and online presence, enhance the Company’s product portfolio and deepen customer relationships across healthcare, government and workplace markets.NexScreen provides point-of-care diagnostic testing solutions to customers a